Puberty blocker bans in the UK and US are not driven by medical evidence. The medications themselves are well-established, used for decades in paediatric care. What has changed is the political will to restrict access for trans young people specifically, regardless of what the science says.
What are puberty blockers, and how long have they been used?
Puberty blockers are medications that pause the hormonal process of puberty. The most commonly used are GnRH analogues, gonadotrophin-releasing hormone analogues, a class of drugs that suppress the sex hormones that drive puberty. They do not cause puberty to go in a different direction. They press pause.
These medications have been in routine paediatric use since the 1980s. Their original and still-widespread application is in the treatment of precocious puberty, a condition where puberty begins abnormally early in a child. In that context, no one calls them experimental. No one frames them as irreversible. No one suggests that prescribing them to an eight-year-old is a dangerous ideological act. They are just the appropriate medical response to an unwanted process happening to a child's body.
When clinicians began using them in the context of gender dysphoria, the medications did not change. The political response to them did.
Why do reversibility claims persist despite the evidence?
The claim that puberty blockers are irreversible is one of the most tenacious pieces of misinformation in this whole debate, and it is wrong, and it keeps circulating anyway.
Biologically, puberty blockers pause puberty. When a young person stops taking them, puberty resumes. That is the mechanism. It is the same mechanism whether the child taking them has precocious puberty or gender dysphoria. The medication does not know the reason it was prescribed. It simply suppresses the hormonal signal, and when it is stopped, the signal returns.
There are legitimate questions worth tracking honestly. Long-term bone density is one: puberty is part of how bones mineralise, and pausing it has implications that deserve monitoring and research. Fertility is another: if a young person moves from blockers onto cross-sex hormones without going through their natal puberty, they may have reduced fertility. These are real considerations, and good gender medicine takes them seriously, discusses them with families, and follows up over time.
But reduced bone density and potential fertility implications are not the same thing as irreversibility. The bones of a young person on blockers are not destroyed. Their fertility is not necessarily gone. And critically, the alternative, going through a puberty that causes significant psychological distress, also has consequences that do not simply reverse. Vocal changes, facial structure, chest development: these are the changes that trans young people and their families are trying to avoid, and many of them are far harder to address later than anything attributable to blockers.
The reversibility claim persists because it is useful rhetorically. It frames the medication as uniquely dangerous in a way that justifies restricting it. And it has been amplified by the Cass Review in the UK, a document that has been widely criticised internationally by gender medicine specialists, researchers, and clinicians, and that relied heavily on sources with a documented pattern of gatekeeping rather than evidence-based care. The Cass Review is not a neutral scientific document, and treating it as settled authority is not a neutral act.
What happened in the UK?
The UK moved to ban the private prescription of puberty blockers for trans young people. NHS prescriptions were already effectively impossible to obtain: the Tavistock clinic, which had been the primary gender service for young people, was closed following the Cass Review, and the replacement regional services have been slow to operationalise, with waiting lists that already ran to years now effectively replaced by a system that cannot see new patients with any reasonable speed.
The private prescription ban removed the last realistic route for many families. Before the ban, a family who could afford it, and access was deeply unequal on income grounds, could see a private clinician and obtain a prescription. That route is now closed. Trans young people in the UK who want to pause puberty have, for practical purposes, no pathway to do so within the country.
The harm is not hypothetical. Puberty does not wait for the politics to settle. Every month that passes is a month of development that a young person experiencing gender dysphoria did not want and cannot easily undo. The distress this causes is well documented. The mental health consequences of untreated gender dysphoria in young people are serious. Framing inaction as the cautious, safe choice ignores this entirely.
What happened in the US?
The US picture has developed rapidly. A wave of state-level legislation, followed by federal executive action, has restricted or banned gender-affirming care for minors across a significant portion of the country. These restrictions include puberty blockers and hormone therapy. In many states, clinicians face legal liability for prescribing them, which has caused some gender clinics to stop offering care entirely, regardless of the state's own legal position, out of fear of professional consequences.
The American Academy of Child and Adolescent Psychiatry reaffirmed its support for evidence-based gender-affirming care in 2025, directly in response to federal pressure. It joined the World Health Organisation, the American Medical Association, the American Academy of Pediatrics, the Endocrine Society, WPATH, the American Psychological Association, and the World Medical Association in supporting access to this care. The professional consensus has not shifted. The political environment has.
For young people in states where care is banned, the options are narrow: travel to a state where care is still accessible, attempt to access care online through services operating in legal states, or go without. All of these options carry significant costs, practical and emotional, and none of them are available equally. A family with resources and flexibility can travel. A family without them cannot.
What do bans actually mean for a young person trying to access care?
They mean going through a puberty that causes them real distress, with no medical option to pause it, while the political argument about whether they deserve care continues around them. They mean watching changes happen to their body that no amount of later treatment will fully undo. Voice, bone structure, chest: these develop during puberty, and while some can be addressed surgically or hormonally later in life, the window to avoid them with blockers closes as puberty progresses.
The ban does not make a young person less trans. It does not resolve the gender dysphoria. It does not make the experience of going through the wrong puberty neutral or harmless. It simply removes the one medical tool that could have made that period bearable, and it leaves the young person and their family to manage the consequences.
People tell me, over and over, about the moment they realised what puberty was going to do to their child's body and what the options were. The relief when they found a pathway to blockers was profound. And the devastation when that pathway was closed, through policy changes, waiting list collapses, or outright bans, has been equally profound. These are not abstractions. These are real children, in real distress, being told by their governments that the distress is not a sufficient reason to act.
Is the evidence base for blockers in gender care genuinely weak?
The evidence base is not as robust as it is for some areas of medicine, and that is partly because it is hard to run large, long-term randomised controlled trials on a relatively small population of young people making decisions about care that intersects with their developing identity. The same is true of many paediatric interventions. Medicine regularly makes decisions on the basis of clinical experience, biological plausibility, patient-reported outcomes, and the best available data, because that is the reality of caring for people.
What the critics of this evidence base rarely apply consistently is the same standard to the evidence for withholding care. The evidence that forcing trans young people through an unwanted puberty is safe and does not cause lasting harm is also not strong, because that too is difficult to study rigorously, and because the harms are distributed over time and across mental health, relationships, and life outcomes in ways that are hard to quantify cleanly. Delay is not neutral. It is a medical decision with consequences, and those consequences deserve the same honest scrutiny as the risks of intervention.
The international professional bodies that have reviewed the evidence and continued to recommend access to puberty blockers for appropriate candidates are not acting recklessly. They are applying the same framework of benefits, risks, and clinical judgement that medicine applies everywhere else.
What can families and young people do now?
In the UK, the private prescription route is closed. NHS routes are effectively inaccessible for most young people in reasonable timeframes. Some families are exploring options in other countries, though this requires resources and carries its own complexities. GenderGP at gendergp.com may be able to help navigate what is currently possible for your specific situation.
In the US, the picture varies by state. In states where care remains legal, gender clinics are still operating. In states where it is restricted, the options are narrower, and a conversation with a clinician who understands the current legal landscape is the right starting point. GenderGP may also be able to help with this.
Whatever the pathway, the young person's wellbeing matters most. Finding affirming adults, whether doctors, therapists, teachers, or family members who understand what this is actually about, matters. And knowing that the political noise around this does not reflect the professional and scientific reality is, I think, at least a small comfort. The evidence did not change. The bans did not happen because medicine decided something new. They happened because politics decided something different, and those are not the same thing.
If there is a topic that you would like me to cover, just let Sammy know.
Dr Helen Webberley is a Gender Specialist, Medical Educator, writer, and advocate, and the founder of GenderGP. She writes about gender diversity, trans healthcare, and the lives at the centre of both.
Comments